Roy Mano1, Cihan Duzgol2, Maz Ganat3, Debra A Goldman4, Kyle A Blum5, Andrew W Silagy6, Aleksandra Walasek7, Alejandro Sanchez8, Renzo G DiNatale7, Julian Marcon9, Mahyar Kashan10, Maria F Becerra11, Nicole E Benfante7, Jonathan A Coleman7, Michael W Kattan12, Paul Russo7, Oguz Akin2, Irina Ostrovnaya4, A Ari Hakimi13. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, Division of Urologic Oncology, Englewood Health, Englewood, NJ. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, University of Texas Health Science Center at Houston, Houston, TX. 6. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, University of Melbourne, Austin Hospital, Melbourne, Australia. 7. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 8. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. 9. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Ludwig-Maximilians-Universität München, Munich, Germany. 10. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, SUNY Downstate Medical Center, Brooklyn, NY. 11. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Miller School of Medicine, University of Miami, Miami, FL. 12. Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH. 13. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: hakimia@mskcc.org.
Abstract
OBJECTIVE: Recurrent genomic alterations in clear cell renal cell carcinoma (ccRCC) have been associated with treatment outcomes; however, current preoperative predictive models do not include known genetic predictors. We aimed to explore the value of common somatic mutations in the preoperative prediction of metastatic disease among patients treated for localized ccRCC. MATERIALS AND METHODS: After obtaining institutional review board approval, data of 254 patients with localized ccRCC treated between 2005 and 2015 who underwent genetic sequencing was collected. The mutation status of VHL, PBRM1, SETD2, BAP1 and KDM5C were evaluated in the nephrectomy tumor specimen, which served as a proxy for biopsy mutation status. The Raj et al. preoperative nomogram was used to predict the 12-year metastatic free probability (MFP). The study outcome was MFP; the relationship between MFP and mutation status was evaluated with Cox-regression models adjusting for the preoperative nomogram variables (age, gender, incidental presentation, lymphadenopathy, necrosis, and size). RESULTS: The study cohort included 188 males (74%) and 66 females (26%) with a median age of 58 years. VHL mutations were present in 152/254 patients (60%), PBRM1 in 91/254 (36%), SETD2 in 32/254 (13%), BAP1 in 19/254 (8%), and KDM5C in 19/254 (8%). Median follow-up for survivors was 8.1 years. Estimated 12-year MFP was 70% (95% CI: 63%-75%). On univariable analysis SETD2 (HR: 3.30), BAP1 (HR: 2.44) and PBRM1 (HR: 1.78) were significantly associated with a higher risk of metastases. After adjusting for known preoperative predictors in the existing nomogram, SETD2 mutations remained associated with a higher rate of metastases after nephrectomy (HR: 2.09, 95% CI: 1.19-3.67, P = 0.011). CONCLUSION: In the current exploratory analysis, SETD2 mutations were significant predictors of MFP among patients treated for localized ccRCC. Our findings support future studies evaluating genetic alterations in preoperative renal biopsy samples as potential predictors of treatment outcome.
OBJECTIVE: Recurrent genomic alterations in clear cell renal cell carcinoma (ccRCC) have been associated with treatment outcomes; however, current preoperative predictive models do not include known genetic predictors. We aimed to explore the value of common somatic mutations in the preoperative prediction of metastatic disease among patients treated for localized ccRCC. MATERIALS AND METHODS: After obtaining institutional review board approval, data of 254 patients with localized ccRCC treated between 2005 and 2015 who underwent genetic sequencing was collected. The mutation status of VHL, PBRM1, SETD2, BAP1 and KDM5C were evaluated in the nephrectomy tumor specimen, which served as a proxy for biopsy mutation status. The Raj et al. preoperative nomogram was used to predict the 12-year metastatic free probability (MFP). The study outcome was MFP; the relationship between MFP and mutation status was evaluated with Cox-regression models adjusting for the preoperative nomogram variables (age, gender, incidental presentation, lymphadenopathy, necrosis, and size). RESULTS: The study cohort included 188 males (74%) and 66 females (26%) with a median age of 58 years. VHL mutations were present in 152/254 patients (60%), PBRM1 in 91/254 (36%), SETD2 in 32/254 (13%), BAP1 in 19/254 (8%), and KDM5C in 19/254 (8%). Median follow-up for survivors was 8.1 years. Estimated 12-year MFP was 70% (95% CI: 63%-75%). On univariable analysis SETD2 (HR: 3.30), BAP1 (HR: 2.44) and PBRM1 (HR: 1.78) were significantly associated with a higher risk of metastases. After adjusting for known preoperative predictors in the existing nomogram, SETD2 mutations remained associated with a higher rate of metastases after nephrectomy (HR: 2.09, 95% CI: 1.19-3.67, P = 0.011). CONCLUSION: In the current exploratory analysis, SETD2 mutations were significant predictors of MFP among patients treated for localized ccRCC. Our findings support future studies evaluating genetic alterations in preoperative renal biopsy samples as potential predictors of treatment outcome.
Authors: Ganesh V Raj; R Houston Thompson; Bradley C Leibovich; Michael L Blute; Paul Russo; Michael W Kattan Journal: J Urol Date: 2008-04-18 Impact factor: 7.450
Authors: Timothy McClure; Art Sedrakyan; Samuel LaRussa; Tianyi Sun; Jialin Mao; Joseph Del Pizzo; Jim Hu Journal: J Vasc Interv Radiol Date: 2020-04-15 Impact factor: 3.464
Authors: Richard W Joseph; Payal Kapur; Daniel J Serie; Jeanette E Eckel-Passow; Mansi Parasramka; Thai Ho; John C Cheville; Eugene Frenkel; Dinesh Rakheja; James Brugarolas; Alexander Parker Journal: Cancer Date: 2013-12-30 Impact factor: 6.860
Authors: Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger Journal: J Mol Diagn Date: 2015-03-20 Impact factor: 5.568
Authors: Patrick O Richard; Michael A S Jewett; Simon Tanguay; Olli Saarela; Zhihui Amy Liu; Frédéric Pouliot; Anil Kapoor; Ricardo Rendon; Antonio Finelli Journal: BJU Int Date: 2016-09-07 Impact factor: 5.588
Authors: Lorenzo Marconi; Saeed Dabestani; Thomas B Lam; Fabian Hofmann; Fiona Stewart; John Norrie; Axel Bex; Karim Bensalah; Steven E Canfield; Milan Hora; Markus A Kuczyk; Axel S Merseburger; Peter F A Mulders; Thomas Powles; Michael Staehler; Borje Ljungberg; Alessandro Volpe Journal: Eur Urol Date: 2015-08-29 Impact factor: 20.096
Authors: Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Alexander Sankin; Abraham A Hakimi; Nina Mikkilineni; Irina Ostrovnaya; Mikhail T Silk; Yupu Liang; Roy Mano; Michael Chevinsky; Robert J Motzer; Stephen B Solomon; Emily H Cheng; Jeremy C Durack; Jonathan A Coleman; Paul Russo; James J Hsieh Journal: Cancer Med Date: 2014-08-14 Impact factor: 4.452
Authors: Thai H Ho; Payal Kapur; Richard W Joseph; Daniel J Serie; Jeanette E Eckel-Passow; Pan Tong; Jing Wang; Erik P Castle; Melissa L Stanton; John C Cheville; Eric Jonasch; James Brugarolas; Alexander S Parker Journal: Mod Pathol Date: 2015-10-30 Impact factor: 7.842